Dengue-specific subviral nanoparticles: Design, creation and characterization

Journal of Nanobiotechnology

Volumn 11, Issue 1, 2013, Pages

  Khetarpal, Niyati ^a   Poddar, Ankur ^a   Nemani, Satish K ^a,b   Dhar, Nisha ^a   Patil, Aravind ^a   Negi, Priyanka ^a   Perween, Ashiya ^a   Viswanathan, Ramaswamy ^a   Lünsdorf, Heinrich ^c   Tyagi, Poornima ^a   Raut, Rajendra ^a   Arora, Upasana ^a   Jain, Swatantra K ^d   Rinas, Ursula ^b,c   Swaminathan, Sathyamangalam ^a   Khanna, Navin ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d HAMDARD UNIVERSITY   (India)

Author keywords

Bionanoparticles; Dengue envelope domain III; Hepatitis B surface antigen; Pichia pastoris; Virus like particle

Indexed keywords

BIONANOPARTICLES; ENVELOPE DOMAINS; HEPATITIS B SURFACE ANTIGEN; PICHIA PASTORIS; VIRUS-LIKE PARTICLES;

ANTIGENS; DIAGNOSIS; MEDICAL APPLICATIONS;

VIRUSES;

ANTIGEN; HEPATITIS B SURFACE ANTIGEN; NANOPARTICLE; S ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; CELL EXTRACT; HYBRID PROTEIN; S ENVELOPE PROTEIN, HEPATITIS B VIRUS; VIRUS ANTIGEN; VIRUS PROTEIN;

ARTICLE; CELL LYSATE; DENGUE VIRUS; GENE DOSAGE; GENE EXPRESSION; MOLECULAR CLONING; NONHUMAN; PICHIA PASTORIS; PROTEIN DOMAIN; VIRUS LIKE AGENT; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; DENGUE; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; PICHIA; PROTEIN TERTIARY STRUCTURE; SPECIES DIFFERENCE; ULTRASTRUCTURE; VERO CELL LINE; VIRION; VIROLOGY;

DENGUE VIRUS; HEPATITIS B VIRUS; PICHIA PASTORIS;

ANIMALS; ANTIGENS, VIRAL; CELL EXTRACTS; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VIRUS; NANOPARTICLES; PICHIA; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SPECIES SPECIFICITY; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRION;

EID: 84878005407     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-11-15     Document Type: Article

References (29)

1. Gubler DJ. The economic burden of dengue. Am J Trop Med Hyg 2012, 86:743-744. 10.4269/ajtmh.2012.12-0157, 3335674, 22556068.
2. Gubler DJ, Kuno G, Markoff L. Flaviviruses. Fields Virology 2007, 1153-1252. Philadelphia: Wolters Kluwer and Lippincott Williams & Wilkins, Knipe DM, Howley PM, 5.
3. WHO Dengue and dengue haemorrhagic fever 2012, Factsheet No117 2012 http://www.who.int/mediacentre/factsheets/fs117/en/, WHO.
4. Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Current Mol Med 2009, 9:152-173.
5. Dussart P, Petit L, Labeau B, Bremand L, Leduc A, Moua D, Matheus S, Baril L. Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. PLoS Negl Trop Dis 2008, 2:e280. 10.1371/journal.pntd.0000280, 2500180, 18714359.
6. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardosa MJ, Devi S, Enria DA, Farrar J, Gubler DJ, Guzman MG, Halstead SB, Hunsperger E, Kliks S, Margolis HS, Nathanson CM, Nguyen VC, Rizzo N, Vázquez S, Yoksan S. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010, Suppl:S30-S37.
7. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY. Strategies for development of dengue virus inhibitors. Antiviral Res 2010, 85:450-462. 10.1016/j.antiviral.2009.12.011, 20060421.
8. Pastorino B, Nougairède A, Wurtz N, Gould E, de Lamballerie X. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs. Antiviral Res 2010, 87:281-294. 10.1016/j.antiviral.2010.04.014, 20452379.
9. Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Patents 2010, 20:819-835.
10. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567. 10.1016/S0140-6736(12)61428-7, 22975340.
11. Soto CM, Ratna BR. Virus hybrids as nanomaterials for biotechnology. Current Opin Biotechnol 2010, 21:426-438.
12. Yildiz I, Shukla S, Steinmetz NF. Applications of viral nanoparticles in medicine. Current Opin Biotechnol 2011, 22:901-908.
13. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007, 6:381-390. 10.1586/14760584.6.3.381, 17542753.
14. Myyryläinen T, Talha SM, Swaminathan S, Vainionpää R, Soukka T, Khanna N, Pettersson K. Simultaneous detection of human immunodeficiency virus 1 and hepatitis B virus infections using a dual-label time-resolved fluorometric assay. J Nanobiotechnol 2010, 8:27.
15. Talha SM, Salminen T, Swaminathan S, Soukka T, Pettersson K, Khanna N. A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2. J Virol Methods 2011, 173:24-30. 10.1016/j.jviromet.2011.01.001, 21232554.
16. Arora U, Tyagi P, Swaminathan S, Khanna N. Dengue virus type 2 envelope domain III displaying bio-nanoparticles. J Nanobiotechnol 2012, 10:30.
17. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007, 81:12816-12826. 10.1128/JVI.00432-07, 2169112, 17881453.
18. Crill WD, Roehrig RT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001, 75:7769-7773. 10.1128/JVI.75.16.7769-7773.2001, 115016, 11462053.
19. Vassileva A, Chugh DA, Swaminathan S, Khanna N. Effect of copy number on the expression levels of Hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris. Protein Exp Purif 2001, 21:71-80.
20. Gurramkonda C, Adnan A, Gäbel T, Lünsdorf H, Ross A, Nemani SK, Swaminathan S, Khanna N, Rinas U. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen. Microb Cell Factories 2009, 8:13.
21. Patil A, Khanna N. Novel membrane extraction procedure for the purification of hepatitis B surface antigen from Pichia pastoris. J Chromatog B 2012, 898:7-14.
22. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman M. Human hepatitis B vaccine from recombinant yeast. Nature 1984, 307:178-180. 10.1038/307178a0, 6318124.
23. Shouval D. Hepatitis B vaccines. J Hepatol 2003, 39:S70-S76.
24. Biemans R, Thines D, Petre-Parent B, de Wilde M, Rutgers T, Cabeźon T. Immunoelectron microscopic detection of the Hepatitis B virus major surface protein in dilated perinuclear membranes of yeast cells. DNA Cell Biol 1992, 11:621-626. 10.1089/dna.1992.11.621, 1388733.
25. Lünsdorf H, Gurramkonda C, Adnan A, Khanna N, Rinas U. Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of hepatitis B surface antigen. Microb Cell Fact 2011, 10:48. 10.1186/1475-2859-10-48, 3142206, 21703024.
26. Batra G, Raut R, Dahiya S, Kamran N, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. J Virol Methods 2010, 167:10-16. 10.1016/j.jviromet.2010.03.002, 20211204.
27. Ludolfs D, Schilling S, Altenschmidt J, Schmitz H. Serological differentiation of infections with dengue virus serotypes 1 to 4 by using recombinant antigens. J Clin Microbiol 2002, 40:4317-4320. 10.1128/JCM.40.11.4317-4320.2002, 139635, 12409419.
28. Khanam S, Pilankatta R, Khanna N, Swaminathan S. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 2009, 27:6011-6021. 10.1016/j.vaccine.2009.07.073, 19665609.
29. Korrapati AB, Swaminathan G, Singh A, Khanna N, Swaminathan S. Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses. PLoS Negl Trop Dis 2012, 6:e1735. 10.1371/journal.pntd.0001735, 3404111, 22848770.